Holen Sie sich die Stockscreener-App
67.56
4.03%
2.62
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records - GlobeNewswire Inc.
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 - GlobeNewswire Inc.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares - Investing.com
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares By Investing.com - Investing.com Nigeria
BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan - Stock Titan
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans - AD HOC NEWS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120 - Moomoo
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Nigeria
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Canada
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BBIO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
BridgeBio Pharma: Attruby Peak Sales Set To Rise - Seeking Alpha
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com Canada
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
BridgeBio at Wells Fargo conference: growth plan centers on 2027 launches - Investing.com India
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
BBIO: Multiple late-stage therapies targeting rare genetic diseases set for US launches by 2027 - TradingView
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain - Benzinga
BridgeBio reports Phase 3 infigratinib achondroplasia data - grafa.com
BridgeBio Oncology Therapeutics, Inc. SEC Filing (Sep 9, 2026) - stocktitan.net
13 Red Days In A Row: BridgeBio Pharma Stock Is Down 11% - Trefis
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Nigeria
BBIO Looks 51.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Canada
BridgeBio’s infigratinib shows improvements in achondroplasia study - investing.com
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
BridgeBio Pharma Reports Favorable Exploratory PROPEL 3 Data for Oral Infigratinib in Achondroplasia, Including Sleep Apnea and Ear Infection Trends - Quiver Quantitative
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com UK
A sleep-apnea measure rose 10.4% with an experimental drug, versus 49.2% with placebo - Stock Titan
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
3.76%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):